Cover Image


Recombinant Drugs to 2020

出版商 Greystone Research Associates 商品編碼 439381
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
重組醫藥品市場 Recombinant Drugs to 2020
出版日期: 2017年02月10日 內容資訊: 英文

本報告以近幾年,大幅度增加的重組醫藥品為焦點,提供FDA (美國食品藥物管理局) 、EMA (歐洲藥品管理局) 認證的生物製藥與主要的疾病市場區隔中其地位、可能性的相關調查,目前已經過核准的生物製藥,生物製藥的主要市場區隔,構成全球生物製藥市場的藥物類別、治療層級、市場區隔,生物製藥採購、商業化的供應鏈動態,各藥物/類型的收益情形,主要的生物製藥供應商,及主要市場區隔的規模與市場佔有率等相關彙整。



  • 生物學的治療藥市場
  • 臨床實驗、醫藥品認證
  • 競爭情形
  • 人口統計,管理護理及成長
  • 需求促進要素、治療要素
  • 疾病的種類、重病度
  • 自我治療
  • 給藥 & 包裝
  • 醫療費償付 & 管理護理
  • 重組醫藥品採購
  • 採購:各企業
  • 採購:各國各地區
  • 採購關係


  • 治療標的
  • 受體,抑制劑及阻斷劑
  • PEG化製劑


  • FDA (美國食品藥物管理局) 認證藥
  • EU (歐洲藥品管理局) 認證藥
  • 已經過核准生技仿製藥


  • 抗血友病因素
  • 抗腫瘤藥物
  • 細胞聚落刺激因子
  • 酵素療法
  • 紅血球生成促進要素
  • 濾泡刺激素
  • 血糖控制
  • 生長激素
  • 非TNF免疫調節劑
  • TNF抑制劑
  • VEGF抑制劑


  • 法規的課題
  • 生技仿製藥
  • 醫療經濟學


Product Code: RDM259K17

In recent years, the number of recombinant drugs - including engineered biological drugs in development - has increased significantly. The pace of this growth is encouraging suppliers to view competitors in new ways. Cooperation between and among drug developers and drug producers is occurring much earlier in the drug development cycle, allowing participants to improve supply chains and time-to-market. The result is a rapidly growing market sector that is changing disease therapeutics on a global scale. This report examines FDA and EMA-approved biological drugs and their position and potential in a dozen major disease segments - markets with important implications for drug developers, contract and supply chain partners and infrastructure participants. Growth prospects for key biological drug therapeutic segments will vary over the forecast period covered in this analysis, influenced by demographic, socioeconomic and competitive factors.

Recombinant Drugs to 2020 - What You Will Learn

  • What are the currently approved biological drugs; their host system, indication(s)?
  • What are the key market segments for biological drugs; what is the competitive picture for each segment?
  • What are the drug classes, therapeutic classes and market segments that comprise the global market for biological drugs?
  • What are the supply chain dynamics of biological drug sourcing and commercialization?
  • What is the revenue picture for each drug/class? What will it look like in 2020?
  • Who are the leading biological drug suppliers, and what are the key collaborations in the sourcing cycle?
  • What is the drug landscape for key market segments? What is the market share? What is the size?

Table of Contents

Executive Summary

Recombinant Drug Market Dynamics

  • The Biological Therapeutics Market Space
  • Clinical Trials and Drug Approvals
  • The Competitive Landscape
  • Demographics, Managed Care and Growth
  • Demand Drivers and Treatment Factors
  • Disease Type and Severity
  • Self-Treatment
  • Administration & Packaging
  • Reimbursement & Managed Care
  • Recombinant Drug Sourcing
  • Sourcing by Company
  • Sourcing by Country/Region
  • Sourcing Relationships

Product Technology Factors

  • Therapeutic Targets
  • Receptors, Inhibitors and Blockers
  • PEGylated Formulations

Recombinant Drug Analysis

  • FDA-Approved Drugs
  • EU-Approved Drugs
  • Approved Biosimilars

Recombinant Drug Market Analysis

  • Antihemophilic Factors
  • Antineoplastics
  • Colony Stimulating Factors
  • Enzyme Therapy
  • Erythropoiesis-stimulating Proteins
  • Follicle Stimulating Hormones
  • Glycemic Control
  • Growth Hormones
  • Non-TNF Immune Modulators
  • TNF Inhibitors
  • VEGF Inhibitors

Market Factors

  • Regulatory Issues
  • Biosimilars
  • Healthcare Economics

Company Profiles

Back to Top